Metoprolol Succinate — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Heart Failure (Symptom Control)

• Furosemide
• Spironolactone

Other medications in Heart & Cardiovascular

• Milrinone
• Moexipril
• Nadolol
• Nebivolol
• Nesiritide
• Nicardipine
• Nifedipine
• Nisoldipine

About Metoprolol Succinate

Metoprolol succinate is a widely prescribed medication crucial for managing various heart conditions. Understanding its role and how to access it affordably is key to your well-being. With TheDrugClub, members can enjoy significant savings on this vital medication, making consistent treatment simpler and more accessible than ever before.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Metoprolol Succinate is approved for (FDA label)

Metoprolol succinate is a beta-adrenergic blocker indicated for the treatment of: • Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Angina Pectoris. (1.2) • Heart Failure, to reduce the risk of cardiovascular mortality and heart failure hospitalizations in patients with heart failure ( 1.3 ) 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol.

Source: Read the full FDA label on DailyMed. Label effective date: September 16, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Metoprolol Succinate (FDA label)

100 mg tablets: White to off-white, round shaped, film coated scored tablets, debossed with I on one side of the score and 100 on the other side. Metoprolol succinate extended-release tablets: 100 mg (3)

Source: FDA prescribing information (DailyMed). Set ID: a46cbf09-20e3-4f0d-ab41-221f60fde068. SPL document ID: 5b9b126e-1b24-6163-e063-6294a90aef50. Label effective date: September 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Metoprolol Succinate (FDA label)

The following adverse reactions are described elsewhere in labeling: • Worsening angina or myocardial infarction. [see Warnings and Precautions (5)] • Worsening heart failure. [see Warnings and Precautions (5)] • Worsening AV block. [see Contraindications (4)] • Most common adverse reactions: tiredness, dizziness, depression, shortness of breath, bradycardia, hypotension, diarrhea, pruritus, rash. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Granules Pharmaceuticals Inc.‚ at 1-877-770-3183 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: a46cbf09-20e3-4f0d-ab41-221f60fde068. SPL document ID: 5b9b126e-1b24-6163-e063-6294a90aef50. Label effective date: September 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Metoprolol Succinate (FDA label)

Metoprolol succinate extended-release tablets are contraindicated in severe bradycardia, second or third degree heart block, cardiogenic shock, decompensated heart failure, sick sinus syndrome (unless a permanent pacemaker is in place), and in patients who are hypersensitive to any component of this product. • Known hypersensitivity to product components. ( 4 ) • Severe bradycardia: Greater than first degree heart block, or sick sinus syndrome without a pacemaker. ( 4 ) • Cardiogenic shock or decompensated heart failure. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: a46cbf09-20e3-4f0d-ab41-221f60fde068. SPL document ID: 5b9b126e-1b24-6163-e063-6294a90aef50. Label effective date: September 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Metoprolol Succinate (FDA label)

N/A • Abrupt cessation may exacerbate myocardial ischemia. ( 5.1 ) • Heart Failure: Worsening cardiac failure may occur. ( 5.2 ) • Bronchospastic Disease: Avoid beta-blockers. ( 5.3 ) • Concomitant use of glycosides, clonidine, diltiazem and verapamil with beta-blockers can increase the risk of bradycardia. ( 5.4 ) • Pheochromocytoma: Initiate therapy with an alpha blocker. ( 5.5 ) • Major Surgery: Avoid initiation of high-dose extended-release metoprolol in patients undergoing non-cardiac surgery.

Source: FDA prescribing information (DailyMed). Set ID: a46cbf09-20e3-4f0d-ab41-221f60fde068. SPL document ID: 5b9b126e-1b24-6163-e063-6294a90aef50. Label effective date: September 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Metoprolol Succinate (FDA label)

• Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7.1 ) • CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7.2 ) • Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7.3 ) 7.1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7.2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to increase metoprolol concentration.

Source: FDA prescribing information (DailyMed). Set ID: a46cbf09-20e3-4f0d-ab41-221f60fde068. SPL document ID: 5b9b126e-1b24-6163-e063-6294a90aef50. Label effective date: September 16, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.